Digital therapeutic software firm Strolll has secured £10.35m for its augmented reality (AR) glasses to help people living with neurological disorders such as Parkinson’s disease, stroke and multiple sclerosis.
The Series A funding round was led by IW Capital, an investment house specialising in providing growth capital for UK SMEs.
Strolll will use the investment to accelerate its sales and marketing activities, extend its product leadership and to expand the regulatory label, allowing the company to target more neuro-related disorders.
Jorgen Ellis, chief executive of Strolll, said: “Strolll are at an exciting inflection point in our journey and we are delighted to be partnering with IW Capital, as well as other investment partners, as we look to accelerate the growth of our business.
“We are positioned at the forefront of the neurorehabilitation market and we’re passionate about helping to improve the care that patients with neurological disorders receive.”
The clinically validated digital therapeutic software platform blends digital content with the real world through using AR glasses to gamify physiotherapy exercises both in clinical and at-home settings.
Seven games have been created using a clinician-led approach to game design to ensure maximum rehabilitation impact for patients, and more games are in the process of being developed.
The technology has also been used to help improve mobility in patients who struggle to walk, balance or are at risk of falling.
Isobel Egemole, investment director at IW Capital, said: “IW Capital are thrilled to announce our investment into Strolll.
“Strolll are transforming the physiotherapy and neurorehabilitation markets and have already helped a significant number of people with debilitating neurological disorders to live better lives.
“The potential impact of their software is huge and we’re proud to be backing this cutting-edge business as it addresses key healthcare needs.”
Results from Strolll’s clinical trials, published in early 2024, showing it to be a safe, well accepted and effective treatment with 8.8/10 usability scores, and 104% patient adherence rate to high intensity neurorehabilitation that has led to significant improvement in patients’ gait and balance.
The trial also found that clinicians using the technologies were able to offer up to seven times more treatments with 67% less staff time, enabling health care services to provide patient care more effectively and efficiently.
Strolll were one of 19 companies selected for the 2024-25 Propel@YH programme, run by Health Innovation Yorkshire & Humber, which supports UK based innovators developing digital health solutions with access to a six-month course of structured support and advice.